Addition of verapamil and tamoxifen to the initial chemotherapy of small cell lung cancer. A phase I/II study - PubMed (original) (raw)
Addition of verapamil and tamoxifen to the initial chemotherapy of small cell lung cancer. A phase I/II study
A Figueredo et al. Cancer. 1990.
Abstract
Based on experimental observations that verapamil and tamoxifen reverse multiple drug resistance, the authors investigated the feasibility of combining both agents with the initial chemotherapy of extensive small cell lung cancer. Overall, in a consecutive series of 58 patients the most important toxicity was myelosuppression, and there was a 24% rate of severe infections. Therapeutic results included 24% complete and 34% partial response rates, median time to disease progression of 32 weeks, and median survival of 46 weeks. In three consecutive cohorts of patients the dose of either tamoxifen or verapamil were escalated by 25% and 33%, respectively. The cohort of patients receiving verapamil 360 mg/day and tamoxifen 100 mg/day (level 2) had slightly more toxicity but also more responses than the other groups. Therefore, the authors recommend that these doses be used in controlled trials to confirm the promising results of their study.
Similar articles
- Pilot study with weekly chemotherapy for patients with extensive small cell lung cancer: an Eastern Cooperative Oncology Group Study (PA586).
Yuen AR, Fuks JZ, Ettinger DS, Chang AY, Ruckdeschel JC, Phan SC, Blum RH. Yuen AR, et al. Cancer J Sci Am. 2000 Jan-Feb;6(1):34-9. Cancer J Sci Am. 2000. PMID: 10696737 Clinical Trial. - Intensive weekly chemotherapy for the treatment of extensive-stage small-cell lung cancer.
Murray N, Shah A, Osoba D, Page R, Karsai H, Grafton C, Goddard K, Fairey R, Voss N. Murray N, et al. J Clin Oncol. 1991 Sep;9(9):1632-8. doi: 10.1200/JCO.1991.9.9.1632. J Clin Oncol. 1991. PMID: 1651995 - A randomized, controlled phase III study of cyclophosphamide, doxorubicin, and vincristine with etoposide (CAV-E) or teniposide (CAV-T), followed by recombinant interferon-alpha maintenance therapy or observation, in small cell lung carcinoma patients with complete responses.
Tummarello D, Mari D, Graziano F, Isidori P, Cetto G, Pasini F, Santo A, Cellerino R. Tummarello D, et al. Cancer. 1997 Dec 15;80(12):2222-9. Cancer. 1997. PMID: 9404698 Clinical Trial. - Small cell lung cancer and chemotherapy.
Nardini S. Nardini S. Monaldi Arch Chest Dis. 1994 Apr;49(2):178-9. Monaldi Arch Chest Dis. 1994. PMID: 8049707 Review. No abstract available.
Cited by
- Multidrug resistance (mdr) genes in human cancer.
Nooter K, Herweijer H. Nooter K, et al. Br J Cancer. 1991 May;63(5):663-9. doi: 10.1038/bjc.1991.152. Br J Cancer. 1991. PMID: 1674875 Free PMC article. Review. No abstract available. - Modulation of doxorubicin-toxicity by tamoxifen in multidrug-resistant tumor cells in vitro and in vivo.
Pommerenke E, Mattern J, Volm M. Pommerenke E, et al. J Cancer Res Clin Oncol. 1994;120(7):422-6. doi: 10.1007/BF01240142. J Cancer Res Clin Oncol. 1994. PMID: 8188736 - Adding high-dose tamoxifen to CHOP does not influence response or survival in aggressive non-Hodgkin's lymphoma: an interim analysis of a randomized phase III trial.
Ezzat AA, Ibrahim EM, Stuart RK, Ajarim D, Bazarbashi S, El-Foudeh MO, Rahal M, Al-Sayed A, Berry J. Ezzat AA, et al. Med Oncol. 2000 Feb;17(1):39-46. doi: 10.1007/BF02826215. Med Oncol. 2000. PMID: 10713659 Clinical Trial. - The chemosensitizer cyclosporin A enhances the toxic side-effects of doxorubicin in the rat.
Van de Vrie W, Jonker AM, Marquet RL, Eggermont AM. Van de Vrie W, et al. J Cancer Res Clin Oncol. 1994;120(9):533-8. doi: 10.1007/BF01221030. J Cancer Res Clin Oncol. 1994. PMID: 7913932
MeSH terms
Substances
LinkOut - more resources
Medical